BreezeBio, a San Francisco, CA-based biotechnology company developing genetic medicines, raised $60 million in a Series B funding round led by Yuanta Investment and DSC Investment.
The round also saw participation from SV Investment, Kiwoom Investment, STIC Ventures, Top Harvest Capital, and others. Existing investors, including DAYLI Partners, Pathway Investment, Loftyrock Investment, Korea Investment Partners, WOORI Venture Partners, KDB Silicon Valley, and ACVC Partners.
Read More:Abram Scientific Raises $11.75M in Series A Funding
The company plans to use the funds to enhance its platform by adding ligands to its nanoparticles for better targeting of specific tissues and cells, including delivery to T cells to support in vivo CAR-T therapy development.
Breeze Bio, Inc., formerly known as GenEdit, is developing BRZ-101, a new immune therapy designed to restore tolerance in type 1 diabetes. The treatment delivers mRNA-encoded autoantigens and supporting factors to antigen-presenting cells, which then present them to T cells in a way that promotes immune tolerance.
The therapy generates antigen-specific regulatory T cells (Tregs) that suppress the autoimmune response without weakening the overall immune system. In preclinical studies, BRZ-101 demonstrated targeted immune tolerance in several autoimmune disease models, including the NOD mouse model of diabetes, and was well tolerated in mice and non-human primates. The company is now preparing BRZ-101 for IND-enabling studies.
BreezeBio’s therapies are powered by its proprietary NanoGalaxy platform. This technology has shown targeted delivery to the immune, heart, lung, and central nervous systems by using specially designed polymers to form nanoparticles that carry the treatment. The company is also enhancing the platform by adding ligands to the nanoparticles for more precise tissue and cell targeting, including delivery to T cells to support in vivo CAR-T therapy development.
“Now that we can precisely deliver genetic treatments to the right cells, we are developing medicines that can truly help patients,” said Kunwoo (Ryan) Lee, PhD, CEO of BreezeBio. “We’ve moved from being a delivery platform company to a therapeutics company, and this funding helps us advance our first programs toward the clinic while continuing to expand the NanoGalaxy platform.”
“BreezeBio is tackling one of the biggest challenges in gene therapy—targeted delivery—and helping shape the next generation of genetic medicines,” said Vincent Jeong, Managing Director at Yuanta Investment and lead Series B investor. “With strong platform validation, progress with a global biotech partner, and clear movement toward the clinic, BreezeBio is reaching a key turning point. We believe the company is well-positioned to become a global genetic medicines developer, and we are proud to support that path.”
About BreezeBio
Founded in 2016 by CEO Kunwoo (Ryan) Lee, BreezeBio is a biotechnology company developing genetic medicines using precise, non-viral delivery. Through its NanoGalaxy® platform, the company creates nanoparticles that deliver genetic material, including mRNA, to specific cells, with proven delivery to immune cells and tissues in the heart, lung, and central nervous system. BreezeBio is building a pipeline focused on autoimmune diseases and cancer, led by BRZ-101 for type 1 diabetes. The company is based in South San Francisco, California.
Read More:Profitmind Raises $9M in Series A Funding
